IN THE SPECIFICATION:

Page 4, line 1, delete the line its entirety and replace it with: -- Groups of derivatized compounds having a general core amidino-urea or diamidino-urea structure have been found to be highly potent interactive compounds which bind to the neuropeptide-Y receptor and may stimulate, not stimulate or partially stimulate a response pathway associated with that receptor thus acting as agonists, partial agonists, antagonists, or mixed agonists- --.

Page 8, line 11 (i.e., first line after the second formula), change "A^1" to --A--.

IN THE CLAIMS:

Cancel claims 1-10 without prejudice or disclaimer.

Rewrite claims 11 and 12 as follows:

11. (Amended) A pharmaceutical composition comprising [any one of the compounds according to Claims 1-10 in] a compound or a pharmaceutically acceptable salt according to claim 13 and a pharmaceutically acceptable carrier.

12. (Amended) A method of treating a mammal in need thereof for a disorder of neuropeptide Y activity comprising administering to said mammal an effective amount of [any one of the compounds of Claims 1-10] a compound or a pharmaceutically acceptable salt according to claim 13.

Add the following new claims 13-25: